Onglyza is a popular drug manufactured by AstraZeneca and used to treat Type 2 Diabetes without ketoacidosis. Recent research has suggested that patients who take Onglyza are at an increased risk of develop heart complications, including heart fail ure. This finding was seen in a 2013 study published in the New England Journal of Medicine (NEJM).
Patients taking part in this study were either given Onglyza or a placebo. The results showed that those patients taking Onglyza had a 27% increase in the rate of hospitalization for heart failure. Because of these alarming results, the FDA met to discuss the drug in April of 2015. 14 of 15 committee panelists voted for an updated Onglyza label that would warn about the risk of increased heart failure. One panel member voted to withdraw Onglyza from the U.S. market.
Heart failure occurs when the heart is unable to pump an adequate supply of blood to meet the body's needs. In some cases, the heart can't fill with enough blood. In others, the heart is unable to pump oxygenated (red) blood to the rest of the body with enough force. Some patients have both problems.
The warning signs of heart failure include:
- Shortness of breath
- Persistent cough or wheezing
- Swelling in the lower extremities or abdomen
- Diminished appetite
- Impaired cognitive ability
- Increased heart rate
If you or a loved one has taken Onglyza and suffered heart failure and/or death, you may have a case for compensation against AstraZeneca. At Reich & Binstock, we are here to help. Contact our lawyers for a free and confidential case evaluation. Call 1-866-LAW-2400 or complete the contact form on this website.